Seres Therapeutics (NASDAQ:MCRB) Downgraded by JPMorgan Chase & Co.

JPMorgan Chase & Co. downgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a neutral rating to an underweight rating in a report released on Thursday morning, MarketBeat reports.

Several other equities research analysts also recently issued reports on MCRB. Chardan Capital restated a “buy” rating and set a $1.25 target price on shares of Seres Therapeutics in a research report on Wednesday, August 14th. StockNews.com cut shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 13th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $10.00 price target on shares of Seres Therapeutics in a research note on Friday, September 13th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $5.08.

Seres Therapeutics Stock Down 0.7 %

MCRB stock opened at $0.70 on Thursday. The stock’s 50 day moving average is $0.89 and its 200-day moving average is $0.92. Seres Therapeutics has a twelve month low of $0.54 and a twelve month high of $2.05. The firm has a market capitalization of $119.97 million, a PE ratio of -0.60 and a beta of 2.03.

Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.08. During the same quarter in the prior year, the business posted $0.36 earnings per share. On average, equities research analysts anticipate that Seres Therapeutics will post -0.95 earnings per share for the current fiscal year.

Insider Transactions at Seres Therapeutics

In other news, insider Teresa L. Young sold 24,480 shares of Seres Therapeutics stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $1.08, for a total value of $26,438.40. Following the sale, the insider now directly owns 78,178 shares in the company, valued at approximately $84,432.24. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last ninety days, insiders sold 28,844 shares of company stock worth $30,104. Company insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Seres Therapeutics in the 1st quarter worth about $39,000. Providence Wealth Advisors LLC increased its stake in shares of Seres Therapeutics by 49.5% during the second quarter. Providence Wealth Advisors LLC now owns 76,250 shares of the biotechnology company’s stock valued at $58,000 after purchasing an additional 25,250 shares in the last quarter. Point72 DIFC Ltd purchased a new position in shares of Seres Therapeutics during the second quarter valued at approximately $64,000. Virtu Financial LLC bought a new stake in shares of Seres Therapeutics in the 1st quarter worth approximately $73,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Seres Therapeutics in the 2nd quarter worth approximately $92,000. Institutional investors own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.